Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting
November 12, 2020 16:15 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented...
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
November 09, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC™ Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting
November 05, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, announced today...
Harpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 04, 2020 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Appoints Omer Siddiqui as VP Development Operations and Project Management
November 03, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference
September 09, 2020 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
September 02, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality Assurance
August 26, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
August 05, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Announces Changes to Board of Directors
July 02, 2020 07:30 ET
|
Harpoon Therapeutics
Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the board Drs. Luke Evnin and Patrick Baeuerle step down from the Harpoon board Dr. Baeuerle remains as...